Page results
-
Elderly patients suffering the most common type of heart attack may benefit from more invasive treatment, new research involving UCLH has shown.
-
Acute loss of sense of smell should be considered globally as a criterion for self-isolation, testing, and contact tracing for Covid-19 infection according to researchers at UCLH and UCL.
-
Information covering a range of conditions. Search by condition name or condition type (specialty).
-
Fears that people with high blood pressure are more at risk from severe Covid-19 because it is easier for the virus to enter their cells and tissues have been laid to rest, thanks to research involving UCLH.
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
Specialist teams at UCLH and UCL are at the forefront of research which could bring hope to people who have been robbed of their sense of smell and taste after suffering the long-term legacy of COVID-19.
-
The hospital marked the start of the year a visit by HM The Queen in February 2020. A few weeks after this celebration, the pandemic took hold and the hospital stepped up to help.
-
UCLH is contributing to a national priority trial of the drug ruxolitinib in patients with Covid-19 pneumonia (infection of the lungs).
File results
-
FOI/2024/0440 - Patient reported outcome measures (PROMs) in oncology
-
FOI/2024/0361 - Recording RTT waiting times: Planned patients guidance
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0532 - Patient treatment/ care/ consent
-
FOI/2024/0543 - Guidelines, policies for the treatment of obesity/ pathways for Tier 3 or Tier 4 weight management services
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer
-
FOI/2024/0357 - Multiple myeloma treatments
-
FOI/2024/0360 - Radiology Information System (RIS) supplier/ contract/ staff details
-
FOI/2024/0371 - Acute myeloid leukaemia treatment
-
FOI/2024/0376 - Advice provided on topical medication for eczema patients